Clinical Trial Update: Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ctDNA-guided changes in therapy for patients with refractory minimal residual disease in colon adenocarcinoma. The study is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Adenocarcinoma
• Colorectal Cancer

Snippet

Sponsor: University of California, Irvine | Conditions: Colon Adenocarcinoma, Colorectal Cancer | Phase 1 | Status: RECRUITING